Raily Aesthetic Medicine International Holdings Limited provided group earnings guidance for the six months ended 30 June 2022. The board of directors of the company informed the shareholders of the company and potential investors that, based on a preliminary assessment of the unaudited management accounts of the Group for the six months ended 30 June 2022 and the information currently available to the Board: the Group is expected to record a revenue of approximately RMB 94 million for the six months ended 30 June 2022 as compared to approximately RMB 91 million for the six months ended 30 June 2021; and the Group is expected to record a profit attributable to the shareholders of the parent of approximately RMB 1 million for the six months ended 30 June 2022 as compared to the loss attributable to the shareholders of the parent of approximately RMB 5 million for the six
months ended 30 June 2021. The Board considers that the expected turnaround in the results for the six months ended 30 June 2022 is mainly attributable to the following reasons: the growth in the performance of aesthetic medical services segment; the decrease in promotion and marketing expenses; and the decrease in exchange loss.